Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 5.04 Million GBP | 1404.65% |
| 2023 | -387 Thousand GBP | 98.12% |
| 2022 | -20.54 Million GBP | 19.91% |
| 2021 | -25.65 Million GBP | -644.49% |
| 2020 | -3.44 Million GBP | 24.43% |
| 2019 | -4.55 Million GBP | 55.74% |
| 2018 | -10.3 Million GBP | -285.55% |
| 2017 | -2.67 Million GBP | 59.06% |
| 2016 | -6.52 Million GBP | -113.38% |
| 2015 | -3.05 Million GBP | 45.04% |
| 2014 | -5.56 Million GBP | -273.24% |
| 2013 | -1.49 Million GBP | 57.74% |
| 2012 | -3.52 Million GBP | -217.64% |
| 2011 | -1.11 Million GBP | 60.74% |
| 2010 | -2.83 Million GBP | -86.31% |
| 2009 | -1.51 Million GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 6.73 Million GBP | 4.76% |
| 2024 Q4 | 5.04 Million GBP | 0.0% |
| 2024 Q1 | 6.43 Million GBP | 1761.5% |
| 2023 Q4 | -387 Thousand GBP | 44.16% |
| 2023 FY | -387 Thousand GBP | 98.12% |
| 2023 Q3 | -693 Thousand GBP | 95.24% |
| 2023 Q1 | -14.88 Million GBP | 27.57% |
| 2023 Q2 | -14.56 Million GBP | 2.14% |
| 2022 Q3 | -10.01 Million GBP | 63.73% |
| 2022 FY | -20.54 Million GBP | 19.91% |
| 2022 Q2 | -27.6 Million GBP | 1.6% |
| 2022 Q1 | -28.05 Million GBP | -9.35% |
| 2022 Q4 | -20.54 Million GBP | -105.21% |
| 2021 Q4 | -25.65 Million GBP | 0.8% |
| 2021 FY | -25.65 Million GBP | -644.49% |
| 2021 Q3 | -25.86 Million GBP | -16.42% |
| 2021 Q2 | -22.21 Million GBP | 0.22% |
| 2021 Q1 | -22.26 Million GBP | -546.14% |
| 2020 Q4 | -3.44 Million GBP | 1.43% |
| 2020 Q1 | -5.78 Million GBP | -26.91% |
| 2020 FY | -3.44 Million GBP | 24.43% |
| 2020 Q2 | -5.78 Million GBP | 0.0% |
| 2020 Q3 | -3.49 Million GBP | 39.59% |
| 2019 Q3 | -4.56 Million GBP | 39.82% |
| 2019 Q4 | -4.55 Million GBP | 0.0% |
| 2019 Q1 | -7.57 Million GBP | 26.46% |
| 2019 Q2 | -7.57 Million GBP | 0.0% |
| 2019 FY | -4.55 Million GBP | 55.74% |
| 2018 Q2 | -4.96 Million GBP | 0.0% |
| 2018 Q1 | -4.96 Million GBP | -85.68% |
| 2018 FY | -10.3 Million GBP | -285.55% |
| 2018 Q4 | -10.3 Million GBP | 0.0% |
| 2018 Q3 | -10.3 Million GBP | -107.65% |
| 2017 Q1 | -4.46 Million GBP | 31.6% |
| 2017 Q4 | -2.67 Million GBP | 0.0% |
| 2017 Q2 | -4.46 Million GBP | 0.0% |
| 2017 FY | -2.67 Million GBP | 59.06% |
| 2017 Q3 | -2.67 Million GBP | 40.15% |
| 2016 Q1 | -1.81 Million GBP | 40.71% |
| 2016 FY | -6.52 Million GBP | -113.38% |
| 2016 Q4 | -6.52 Million GBP | 0.0% |
| 2016 Q3 | -6.52 Million GBP | -259.89% |
| 2016 Q2 | -1.81 Million GBP | 0.0% |
| 2015 Q4 | -3.05 Million GBP | 0.0% |
| 2015 FY | -3.05 Million GBP | 45.04% |
| 2015 Q3 | -3.05 Million GBP | 28.89% |
| 2015 Q2 | -4.3 Million GBP | 0.0% |
| 2015 Q1 | -4.3 Million GBP | 22.71% |
| 2014 Q3 | -5.56 Million GBP | 12.97% |
| 2014 Q2 | -6.39 Million GBP | 0.0% |
| 2014 Q1 | -6.39 Million GBP | -328.88% |
| 2014 FY | -5.56 Million GBP | -273.24% |
| 2014 Q4 | -5.56 Million GBP | 0.0% |
| 2013 Q4 | -1.49 Million GBP | 0.0% |
| 2013 FY | -1.49 Million GBP | 57.74% |
| 2013 Q2 | -2.56 Million GBP | 0.0% |
| 2013 Q3 | -1.49 Million GBP | 41.93% |
| 2012 Q2 | -1.91 Million GBP | 0.0% |
| 2012 FY | -3.52 Million GBP | -217.64% |
| 2012 Q4 | -3.52 Million GBP | 0.0% |
| 2011 Q4 | -1.11 Million GBP | 0.0% |
| 2011 FY | -1.11 Million GBP | 60.74% |
| 2011 Q2 | -1.74 Million GBP | 0.0% |
| 2010 FY | -2.83 Million GBP | -86.31% |
| 2009 FY | -1.51 Million GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 67.969% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -22.607% |
| SQZ Biotechnologies Company | -36.23 Million USD | 113.933% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 88.201% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 180.085% |
| Mesoblast Limited | 55.85 Million USD | 90.961% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -444.551% |
| Genus plc | 190.6 Million USD | 97.351% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -125.822% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -315.936% |
| Marizyme, Inc. | 18.56 Million USD | 72.81% |
| ContraFect Corporation | -6.02 Million USD | 183.787% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -642.5% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -3650.028% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -336.981% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -125.177% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 8.232% |
| MultiCell Technologies, Inc. | 90.04 USD | -5607407.774% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 787.895% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 61.0% |
| EV Biologics, Inc. | 1.36 Million USD | -269.087% |
| Q BioMed Inc. | 4.06 Million USD | -24.359% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 83.475% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -711.262% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -401.034% |
| Biomind Labs Inc. | 711.4 Thousand USD | -609.725% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 95.402% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 60.575% |
| Skye Bioscience, Inc. | -5.72 Million USD | 188.248% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -486.929% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3511.485% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 10.611% |
| IMV Inc. | 7.67 Million USD | 34.177% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -25314.003% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -129.294% |
| GB Sciences, Inc. | 1.74 Million USD | -188.957% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2847.187% |
| HST Global, Inc. | 96.79 Thousand USD | -5116.286% |
| CSL Limited | 10.52 Billion USD | 99.952% |
| Halberd Corporation | 144.72 Thousand USD | -3388.782% |
| Enzolytics Inc. | 981.65 Thousand USD | -414.335% |
| Resverlogix Corp. | 6.45 Million USD | 21.733% |
| Affymax, Inc. | -5.59 Million USD | 190.209% |
| SYBLEU INC | 473.71 Thousand USD | -965.833% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 850.124% |
| argenx SE | -2.02 Billion USD | 100.249% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 88.375% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 110.74% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -86.405% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 157.116% |
| AVAX Technologies, Inc. | -5.9 Million USD | 185.53% |
| Zenith Capital Corp. | 10.06 Thousand USD | -50068.919% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.476% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -2419.059% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -111.606% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2969.133% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 91.661% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -152.527% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 296.457% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1303.631% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 75.099% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 27663.053% |
| BioStem Technologies, Inc. | 4.47 Million USD | -12.902% |
| ONE Bio Corp. | 9.04 Million USD | 44.148% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -2408.77% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 385519.847% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -2348.392% |
| Agentix Corp. | 37.63 Thousand USD | -13317.129% |
| LadRx Corporation | -2.03 Million USD | 347.929% |
| Cell Source, Inc. | 9.23 Million USD | 45.31% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 24840.298% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -694.909% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -694.909% |
| NovAccess Global Inc. | 2.17 Million USD | -131.769% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 28.595% |
| Itoco Inc. | 228.3 Thousand USD | -2111.515% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -3612.8% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -1.856% |
| Kadimastem Ltd | -253.1 Thousand USD | 2094.848% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1156.442% |
| CytoDyn Inc. | 20.26 Million USD | 75.081% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 780470.943% |
| Mobile Lads Corp. | 484.23 Thousand USD | -942.682% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 54575.775% |
| Qrons Inc. | 351.42 Thousand USD | -1336.714% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 34.48% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2122.674% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1555.41% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -13.282% |
| International Stem Cell Corporation | 2.59 Million USD | -94.942% |
| Bioxytran, Inc. | 1.89 Million USD | -165.889% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7989.661% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -131.51% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -47.03% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 40.968% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -553.502% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 503.92% |
| Neutra Corp. | 52.18 Thousand USD | -9574.823% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 302.853% |
| PureTech Health plc | -167.19 Million USD | 103.02% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2161.59% |
| IXICO plc | -4.44 Million USD | 213.599% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 61.805% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 90.795% |
| CSL Limited | 10.52 Billion USD | 99.952% |
| Cellectis S.A. | -43.81 Million USD | 111.522% |